CY1123203T1 - Δοσολογικο σχημα για χαμενες δοσεις για ενεσιμους εστερες παλιπεριδονης μακρας δρασης - Google Patents

Δοσολογικο σχημα για χαμενες δοσεις για ενεσιμους εστερες παλιπεριδονης μακρας δρασης

Info

Publication number
CY1123203T1
CY1123203T1 CY20201100618T CY201100618T CY1123203T1 CY 1123203 T1 CY1123203 T1 CY 1123203T1 CY 20201100618 T CY20201100618 T CY 20201100618T CY 201100618 T CY201100618 T CY 201100618T CY 1123203 T1 CY1123203 T1 CY 1123203T1
Authority
CY
Cyprus
Prior art keywords
paliperidone
long
dosage forms
missed doses
injectable
Prior art date
Application number
CY20201100618T
Other languages
English (en)
Inventor
Paulien Gerarda Maria RAVENSTIJN
Alberto Russu
Mahesh Narain Samtani
Srihari Gopal
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123203(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1123203T1 publication Critical patent/CY1123203T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφαρμογή παρέχει μία μέθοδο για θεραπεία ασθενούς που έχουν ανάγκη ψυχιατρικής θεραπείας, όπου ο αναφερόμενος ασθενής υποβάλλεται σε θεραπευτική αγωγή με το 3-μηνο σκεύασμα παλμιτικής παλιπεριδόνης και αποτυγχάνει να λάβει την επόμενη προγραμματισμένη δόση του 3-μηνου σκευάσματος παλμιτικής παλιπεριδόνης.
CY20201100618T 2015-04-07 2020-07-06 Δοσολογικο σχημα για χαμενες δοσεις για ενεσιμους εστερες παλιπεριδονης μακρας δρασης CY1123203T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US201562162596P 2015-05-15 2015-05-15
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
CY1123203T1 true CY1123203T1 (el) 2021-10-29

Family

ID=57072843

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100618T CY1123203T1 (el) 2015-04-07 2020-07-06 Δοσολογικο σχημα για χαμενες δοσεις για ενεσιμους εστερες παλιπεριδονης μακρας δρασης

Country Status (27)

Country Link
US (1) US10143693B2 (el)
EP (3) EP3280416B1 (el)
JP (3) JP6728221B2 (el)
KR (2) KR20230162162A (el)
AU (3) AU2016244801B2 (el)
BR (1) BR112017021383A2 (el)
CA (2) CA2925908C (el)
CY (1) CY1123203T1 (el)
DK (2) DK3280416T3 (el)
EA (1) EA037185B1 (el)
ES (2) ES2967585T3 (el)
FI (1) FI3744326T3 (el)
HK (1) HK1249047A1 (el)
HR (2) HRP20240022T1 (el)
HU (2) HUE065435T2 (el)
IL (2) IL254669B2 (el)
LT (2) LT3744326T (el)
MA (1) MA41917B1 (el)
MD (2) MD3744326T2 (el)
NZ (2) NZ758246A (el)
PL (2) PL3280416T3 (el)
PT (2) PT3280416T (el)
RS (2) RS60510B1 (el)
SI (2) SI3744326T1 (el)
TW (1) TWI694825B (el)
UA (1) UA118732C2 (el)
WO (1) WO2016164218A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6728221B2 (ja) 2015-04-07 2020-07-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
CA3077224A1 (en) 2017-10-27 2019-05-02 Shandong Luye Pharmaceutical Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
CA3203015A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
CN116528837A (zh) * 2020-11-30 2023-08-01 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
RS65612B1 (sr) 2020-11-30 2024-07-31 Janssen Pharmaceutica Nv Metodi za osiguravanje resuspenzije formulacija paliperidon palmitata
JP2023552329A (ja) 2020-11-30 2023-12-15 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
LT4025187T (lt) * 2020-11-30 2024-02-12 Janssen Pharmaceutica Nv Dozavimo režimai, susiję su prailginto atpalaidavimo injekcinėmis paliperidono vaisto formomis
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR20240052810A (ko) * 2021-08-30 2024-04-23 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1879890A1 (en) 2005-04-25 2008-01-23 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
CN105560176A (zh) * 2007-12-19 2016-05-11 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
US8758780B2 (en) * 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
JP6728221B2 (ja) 2015-04-07 2020-07-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン

Also Published As

Publication number Publication date
JP7228503B2 (ja) 2023-02-24
EA201792209A1 (ru) 2018-02-28
EA037185B1 (ru) 2021-02-17
LT3744326T (lt) 2023-12-27
HRP20240022T1 (hr) 2024-03-29
AU2016244801A1 (en) 2017-10-05
RS65024B1 (sr) 2024-01-31
EP3280416A4 (en) 2019-01-23
US10143693B2 (en) 2018-12-04
EP4349323A2 (en) 2024-04-10
DK3744326T3 (da) 2024-02-05
AU2020239611B2 (en) 2022-07-21
MD3744326T2 (ro) 2024-05-31
EP3280416B1 (en) 2020-04-22
EP3280416A1 (en) 2018-02-14
US20170281629A1 (en) 2017-10-05
MD3280416T2 (ro) 2020-10-31
IL254669B1 (en) 2024-01-01
FI3744326T3 (fi) 2024-02-02
IL254669B2 (en) 2024-05-01
ES2802299T3 (es) 2021-01-18
WO2016164218A1 (en) 2016-10-13
PL3744326T3 (pl) 2024-03-25
KR20230162162A (ko) 2023-11-28
HK1249047A1 (zh) 2018-10-26
IL254669A0 (en) 2017-11-30
NZ735952A (en) 2022-02-25
PT3280416T (pt) 2020-06-30
IL309340A (en) 2024-02-01
JP2020090498A (ja) 2020-06-11
HUE065435T2 (hu) 2024-05-28
DK3280416T3 (da) 2020-05-11
NZ758246A (en) 2024-05-31
CA3088401A1 (en) 2016-10-07
AU2022221405B2 (en) 2024-08-01
JP7422277B2 (ja) 2024-01-26
LT3280416T (lt) 2020-06-25
JP2018510894A (ja) 2018-04-19
PT3744326T (pt) 2024-01-15
JP6728221B2 (ja) 2020-07-22
CA2925908A1 (en) 2016-10-07
EP3744326A1 (en) 2020-12-02
HUE049485T2 (hu) 2020-09-28
AU2016244801B2 (en) 2020-06-25
EP4349323A3 (en) 2024-06-12
EP3744326B1 (en) 2023-12-06
KR102606678B1 (ko) 2023-11-24
CA2925908C (en) 2020-09-01
HRP20201027T1 (hr) 2020-12-11
PL3280416T3 (pl) 2020-12-14
AU2020239611A1 (en) 2020-10-15
UA118732C2 (uk) 2019-02-25
RS60510B1 (sr) 2020-08-31
JP2021130680A (ja) 2021-09-09
TWI694825B (zh) 2020-06-01
SI3744326T1 (sl) 2024-02-29
SI3280416T1 (sl) 2020-07-31
BR112017021383A2 (pt) 2018-07-03
MA41917B1 (fr) 2020-07-29
AU2022221405A1 (en) 2022-09-15
TW201642863A (zh) 2016-12-16
ES2967585T3 (es) 2024-05-03
KR20170134583A (ko) 2017-12-06

Similar Documents

Publication Publication Date Title
CY1123203T1 (el) Δοσολογικο σχημα για χαμενες δοσεις για ενεσιμους εστερες παλιπεριδονης μακρας δρασης
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125058T1 (el) Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MY194341A (en) Method of treating a brain tumor
EA201790442A1 (ru) Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
CY1123982T1 (el) Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)
CY1120075T1 (el) Καρβορανυλο-πορφυρινες για χρηση στη θεραπεια του καρκινου
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
AR102871A1 (es) Métodos de tratamiento de fibrosis
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
CY1122708T1 (el) Ενωσεις οξα-διαζασπειρο με δραση εναντι του πονου
BR112018002763A2 (pt) método para cicatrização de ferimentos
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией